Y
Yves Pommier
Researcher at National Institutes of Health
Publications - 847
Citations - 65543
Yves Pommier is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Topoisomerase & DNA. The author has an hindex of 123, co-authored 789 publications receiving 58898 citations. Previous affiliations of Yves Pommier include Purdue University & Kyushu University.
Papers
More filters
Proceedings ArticleDOI
Abstract CN05-01: PARP inhibitors: Trapping of PARP and rational for combinations.
TL;DR: The genetic and biochemical evidence that PARP inhibitors act as cytotoxic anticancer agents by trapping PARP-DNA complexes is reviewed and it is proposed thatPARP trapping results from allosteric effect whereas catalytic inhibition results from competition with NAD+.
Proceedings ArticleDOI
Abstract 75: CellMiner, a systems pharmacological web-application for the NCI-60 cancerous cell-lines: Updates, data integration, and translationally relevant results
Journal ArticleDOI
MA12.03 PARP Inhibitor Sensitivity Does Not Depend on BAP1 but Is Enhanced by Temozolomide in MGMT Deficient Human Mesothelioma Cells
Daniel Rathkey,M. Khanal,Junko Murai,Jingli Zhang,Qun Jiang,Betsy Morrow,Christine N. Evans,Raj Chari,Manjistha Sengupta,Anish Thomas,Yves Pommier,Raffit Hassan +11 more
Proceedings ArticleDOI
Abstract 4632: Plasma and tumor pharmacokinetics of IV LMP400, a novel indenoisoquinoline topoisomerase I inhibitor, in a canine phase I study
Julie L. Eiseman,Julianne L. Holleran,David L. McCormick,Miguel Muzzio,Joseph M. Covey,Chand Khanna,Christina Mazcko,Yves Pommier,Melissa Paoloni,James D. Doroshow,Joseph E. Tomaszewski,Jan H. Beumer +11 more
TL;DR: The plasma pharmacokinetics of LMP400 in dogs display biphasic behavior, a relatively high total body clearance at 19.5 L/h/m2, and a terminal half-life of 29.7 h, which may be a valuable distinction in the translation of this novel indenoisoquinoline to the clinic.
Proceedings ArticleDOI
Abstract C278: Topoisomerase 1 immunoassay provides proof of target engagement by the indenoisoquinoline class of topoisomerase 1 inhibitors in canine lymphomas.
Thomas D. Pfister,Katerine V. Ferry-Galow,Tariq Mohabbat,Robert J. Kinders,Chand Khanna,Christina Mazcko,Ralph E. Parchment,Yves Pommier,Joseph E. Tomaszewski,James H. Doroshow +9 more
TL;DR: Baseline Top1 levels in canine lymphoma patients varied greatly, consistent with previous findings in xenografts and a limited number of human tumor biopsies, and evidence of target engagement by the indenoisoquinoline class of topoisomerase 1 inhibitor is provided.